Hiroshi Sootome

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 938 citations · Full text

Medicine, Oncology, Pharmacology +17

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 198 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa et al. · ACS Medicinal Chemistry Letters · 2023 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

Love Goyal, Daniel DiToro, Francesco Facchinetti et al. · Annals of Oncology · 2024 · 33 citations · Full text

Medicine, Cancer Biology, Oncology +14

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh et al. · Molecular Cancer Therapeutics · 2013 · 28 citations

Medicine, Oncology, Pharmacology +13